Pfizer's New NSCLC ADC Flops in Phase 3, but Combinations Could Revive the Program
TL;DR
Pfizer’s first new ADC after acquiring Seagen failed to meet its primary endpoint in a phase 3 nonsquamous NSCLC trial, showing no significant overall survival advantage vs docetaxel. The company cites a stronger signal in a patient subgroup with one prior therapy and notes ongoing phase 3 studies combining sigvotatug vedotin with pembrolizumab in first-line NSCLC, sustaining optimism for the program despite the setback.
- Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial Fierce Biotech
- Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial Endpoints News
- Closely watched Pfizer lung cancer drug falls short in clinical trial statnews.com
- Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire
- PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug Yahoo Finance
Want the full story? Read the original reporting
Read on Fierce Biotech